Clinical trial
A Phase I Study of SAHA in Combination With Bortezomib in Relapsed and Refractory Multiple Myeloma
NCT00310024 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of SAHA in Combination With Bortezomib in Relapsed and Refractory Multiple Myeloma
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2005
- Completion date
- Not reported
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
refractory multiple myeloma, stage i multiple myeloma, stage ii multiple myeloma, stage iii multiple myeloma